Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric left ventricular hypertrophy, diastolic dysfunction and myocardial disarray. HCM is caused by mutations in sarcomeric genes, but in >40% of patients, the mutation is not yet identified. We hypothesized that FHL1, encoding four-and-a-half-LIM domains 1, could be another disease gene since it has been shown to cause distinct myopathies, sometimes associated with cardiomyopathy. We evaluated 121 HCM patients, devoid of a mutation in known disease genes. We identified three novel variants in FHL1 (c.134delA/K45Sfs, c.459C>A/C153X and c.827G>C/C276S). Whereas the c.459C>A variant was associated with muscle weakness in some patients, the c.134delA and c.827G>C variants were associated with isolated HCM. Gene transfer of the latter variants in C2C12 myoblasts and cardiac myocytes revealed reduced levels of FHL1 mutant proteins, which could be rescued by proteasome inhibition. Contractility measurements after adeno-associated virus transduction in rat-engineered heart tissue (EHT) showed: (i) higher and lower forces of contraction with K45Sfs and C276S, respectively, and (ii) prolonged contraction and relaxation with both mutants. All mutants except one activated the fetal hypertrophic gene program in EHT. In conclusion, this study provides evidence for FHL1 to be a novel gene for isolated HCM. These data, together with previous findings of proteasome impairment in HCM, suggest that FHL1 mutant proteins may act as poison peptides, leading to hypertrophy, diastolic dysfunction and/or altered contractility, all features of HCM.

[1]  L. Carrier,et al.  Genetics of hypertrophic and dilated cardiomyopathy. , 2012, Current pharmaceutical biotechnology.

[2]  L. Carrier,et al.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice , 2012, Journal of Muscle Research and Cell Motility.

[3]  E. R. Paalberends,et al.  Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function , 2012, Circulation. Heart failure.

[4]  C. Schalkwijk,et al.  Original Contribution , 1988 .

[5]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[6]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[7]  Thomas Rau,et al.  Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology , 2011, PloS one.

[8]  L. Carrier,et al.  The ubiquitin–proteasome system in cardiomyopathies , 2011, Current opinion in cardiology.

[9]  L. Carrier,et al.  Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. , 2011, Journal of molecular and cellular cardiology.

[10]  C. Mitchell,et al.  Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: A comprehensive review of the clinical, histological and pathological features , 2011, Neuromuscular Disorders.

[11]  J. Li,et al.  Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. , 2010, Cardiovascular research.

[12]  T. Bird,et al.  A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: Phenotypic spectrum and structural study of FHL1 mutations , 2010, Journal of the Neurological Sciences.

[13]  M. Bönstrup,et al.  Development of a Drug Screening Platform Based on Engineered Heart Tissue , 2010, Circulation research.

[14]  F. Pagani,et al.  Ubiquitin Proteasome Dysfunction in Human Hypertrophic and Dilated Cardiomyopathies , 2010, Circulation.

[15]  H. Goebel,et al.  Familial Reducing Body Myopathy with Cytoplasmic Bodies and Rigid Spine Revisited: Identification of a Second LIM Domain Mutation in FHL1 , 2010, Neuropediatrics.

[16]  Xuejun Wang,et al.  The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. , 2010, Cardiovascular research.

[17]  S. Lecker,et al.  Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. , 2010, Cardiovascular research.

[18]  A. Spuler,et al.  Contractures and hypertrophic cardiomyopathy in a novel FHL1 mutation , 2010, Annals of neurology.

[19]  M. Gautel,et al.  Distinct Sarcomeric Substrates Are Responsible for Protein Kinase D-mediated Regulation of Cardiac Myofilament Ca2+ Sensitivity and Cross-bridge Cycling* , 2009, The Journal of Biological Chemistry.

[20]  S. Heath,et al.  Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. , 2009, American journal of human genetics.

[21]  H. Goebel,et al.  Consequences of mutations within the C terminus of the FHL1 gene , 2009, Neurology.

[22]  NicolasVignier,et al.  Nonsense-Mediated mRNA Decay and Ubiquitin–Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice , 2009 .

[23]  E. Arbustini,et al.  A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. , 2009, European heart journal.

[24]  F. Muntoni,et al.  Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. , 2009, Brain : a journal of neurology.

[25]  F. T. ten Cate,et al.  Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.

[26]  I. Nonaka,et al.  NOVEL FHL1 MUTATIONS IN FATAL AND BENIGN REDUCING BODY MYOPATHY , 2009, Neurology.

[27]  Kortaro Tanaka,et al.  Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[28]  I. Hisatome,et al.  Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. , 2008, Journal of molecular biology.

[29]  Susan S. Brown,et al.  Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy , 2008, The Journal of cell biology.

[30]  M. Willis,et al.  The ubiquitin-proteasome system in cardiac dysfunction. , 2008, Biochimica et biophysica acta.

[31]  A. McCulloch,et al.  An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. , 2008, The Journal of clinical investigation.

[32]  I. Nonaka,et al.  Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1) , 2008, Neuromuscular Disorders.

[33]  W. Seeger,et al.  Fhl-1, a New Key Protein in Pulmonary Hypertension , 2008, Circulation.

[34]  H. Katus,et al.  Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats , 2008, Gene Therapy.

[35]  K. Murray,et al.  Four and a half LIM protein 1: a partner for KCNA5 in human atrium. , 2008, Cardiovascular research.

[36]  J. Golden,et al.  Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy. , 2008, The Journal of clinical investigation.

[37]  K. Wilhelmsen,et al.  X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. , 2008, American journal of human genetics.

[38]  A. Noor,et al.  An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. , 2008, American journal of human genetics.

[39]  L. Carrier,et al.  Cardiac Myosin-Binding Protein C Is Required for Complete Relaxation in Intact Myocytes , 2007, Circulation research.

[40]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[41]  B. Horne,et al.  Nonsense Mutations in hERG Cause a Decrease in Mutant mRNA Transcripts by Nonsense-Mediated mRNA Decay in Human Long-QT Syndrome , 2007, Circulation.

[42]  I. Nonaka,et al.  Unfolded protein response and aggresome formation in hereditary reducing‐body myopathy , 2007, Muscle & nerve.

[43]  H. Worman,et al.  Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins. , 2006, Biochemical and biophysical research communications.

[44]  P. Charron,et al.  The genetic bases of cardiomyopathies , 2006 .

[45]  Susan S. Brown,et al.  Four and a Half LIM Protein 1 Binds Myosin-binding Protein C and Regulates Myosin Filament Formation and Sarcomere Assembly* , 2006, Journal of Biological Chemistry.

[46]  J. Towbin,et al.  Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children , 2005, Circulation.

[47]  K. Lindenberg,et al.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.

[48]  S. Liggett,et al.  Common Genomic Response in Different Mouse Models of &bgr;-Adrenergic–Induced Cardiomyopathy , 2003, Circulation.

[49]  Susan S. Brown,et al.  Skeletal muscle LIM protein 1 regulates integrin-mediated myoblast adhesion, spreading, and migration. , 2003, American journal of physiology. Cell physiology.

[50]  C. Seidman.  Genetic causes of inherited cardiac hypertrophy: Robert L. Frye Lecture. , 2002, Mayo Clinic proceedings.

[51]  Roger J Hajjar,et al.  Titin Isoform Switch in Ischemic Human Heart Disease , 2002, Circulation.

[52]  A. Bosserhoff,et al.  The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus , 2002, The EMBO journal.

[53]  A. Marian,et al.  Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. , 2001, Journal of the American College of Cardiology.

[54]  S. Tsui,et al.  Characterization of tissue‐specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM‐only protein (FHL1) , 2001, Journal of Cellular Biochemistry.

[55]  Qiang Zhou,et al.  Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system , 2000, Mechanisms of Development.

[56]  I. Bach.  The LIM domain: regulation by association , 2000, Mechanisms of Development.

[57]  Susan S. Brown,et al.  Characterization of Two Isoforms of the Skeletal Muscle LIM Protein 1, SLIM1 , 1999, The Journal of Biological Chemistry.

[58]  Wolfgang A. Linke,et al.  I-Band Titin in Cardiac Muscle Is a Three-Element Molecular Spring and Is Critical for Maintaining Thin Filament Structure , 1999, The Journal of cell biology.

[59]  M. Komajda,et al.  Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. , 1998, European heart journal.

[60]  T. Honjo,et al.  LIM Protein KyoT2 Negatively Regulates Transcription by Association with the RBP-J DNA-Binding Protein , 1998, Molecular and Cellular Biology.

[61]  K P Fung,et al.  A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. , 1997, Circulation.

[62]  H. A. Louis,et al.  Mutational analysis of the metal sites in an LIM domain. , 1994, The Journal of biological chemistry.

[63]  V. Ferrans,et al.  Specificity of light and electron microscopic features of hypertrophic obstructive and nonobstructive cardiomyopathy. Qualitative, quantitative and etiologic aspects. , 1983, European heart journal.

[64]  M. Sauer,et al.  Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy , 2011, Basic Research in Cardiology.

[65]  Yiming Wu,et al.  Cardiac titin: structure, functions and role in disease. , 2007, Clinica chimica acta; international journal of clinical chemistry.